Over 300 patients randomized in Ocular Therapeutix’s SOL-1 phase 3 trial for OTX-TKI
SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA).
Related Articles
EUNOS 2024
A report from the 16th European Neuro-Ophthalmology Society Meeting held in The Netherlands. Find out more with The Ophthalmologist
Glaukos submits NDA to FDA for Epioxa
Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.
Advanced therapies for retinal vascular diseases
Enhancing durability and reducing treatment burden.
Mental health and awareness gaps hinder diabetic eye screenings
Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.
Effects of Ocular Residual Astigmatism on Refractive Outcomes for Myopia Correction After Keratorefractive Lenticule Extraction Surgery | Journal of Refractive Surgery
Purpose To evaluate the effects of ocular residual astigmatism (ORA) on refractive outcomes for patients with astigmatism after keratorefractive lenticule extraction (KLEx) and to identify…
Reviews Supplements RP-Year in Review
Wills Eye Resident Series : A patient presents with decreased vision after an injury , p. 62 medicare Q & A 2024 Reimbursement Update Wills…
Bevacizumab for Retinopathy of Prematurity is Not Associated With Systemic Hypertension | Journal of Pediatric Ophthalmology & Strabismus
Purpose: To evaluate for an association between systemic hypertension and intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP) treatment, due to a 2020 case report…
Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US
This economic evaluation study estimates the economic burden of late-stage age-related macular degeneration in 3 countries.
Curacle presents results of its phase 2a clinical trial of CU06 for DME
Ophthalmology Times – ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
Glaukos submits NDA to FDA for Epioxa
Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.